JP2022501428A5 - - Google Patents
Info
- Publication number
- JP2022501428A5 JP2022501428A5 JP2021539483A JP2021539483A JP2022501428A5 JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5 JP 2021539483 A JP2021539483 A JP 2021539483A JP 2021539483 A JP2021539483 A JP 2021539483A JP 2022501428 A5 JP2022501428 A5 JP 2022501428A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence shown
- hcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732334P | 2018-09-17 | 2018-09-17 | |
| US201862732299P | 2018-09-17 | 2018-09-17 | |
| US62/732,334 | 2018-09-17 | ||
| US62/732,299 | 2018-09-17 | ||
| PCT/US2019/051529 WO2020061059A1 (en) | 2018-09-17 | 2019-09-17 | Anti-lilrb2 antibodies and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022501428A JP2022501428A (ja) | 2022-01-06 |
| JP2022501428A5 true JP2022501428A5 (enExample) | 2022-09-29 |
Family
ID=69888746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021539483A Pending JP2022501428A (ja) | 2018-09-17 | 2019-09-17 | 抗ｌｉｌｒｂ２抗体およびその使用の方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12157768B2 (enExample) |
| EP (1) | EP3852805A4 (enExample) |
| JP (1) | JP2022501428A (enExample) |
| KR (1) | KR20210108940A (enExample) |
| CN (1) | CN113543804A (enExample) |
| AU (1) | AU2019343131A1 (enExample) |
| CA (1) | CA3111862A1 (enExample) |
| WO (1) | WO2020061059A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY201995A (en) | 2018-07-09 | 2024-03-28 | Five Prime Therapeutics Inc | Antibodies binding to ilt4 |
| JP2023510132A (ja) * | 2019-12-20 | 2023-03-13 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｐｄ－１アンタゴニスト、ｉｌｔ４アンタゴニストおよび化学療法剤の組合せを使用して癌を治療する方法 |
| US11834512B2 (en) | 2020-05-04 | 2023-12-05 | The Regents Of The University Of California | Inhibiting anti-ENPP1 antibodies |
| JP2023541656A (ja) * | 2020-09-17 | 2023-10-03 | メルク・シャープ・アンド・ドーム・エルエルシー | 癌を治療するための抗ｉｌｔ４抗体またはそれと抗ｐｄ－１抗体との組合せの投与レジメン |
| EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
| EP4232087A4 (en) * | 2020-10-21 | 2024-10-09 | Immune-ONC Therapeutics, Inc. | NOVEL ANTI-LILRB2 ANTIBODIES AND DERIVED PRODUCTS |
| MX2023010661A (es) * | 2021-03-11 | 2023-11-28 | Univ Health Network | Moléculas de union al receptor leucocitario humano similar a inmunoglobulina b1 (lilrb1) y al receptor leucocitario humano similar a inmunoglobulina b2 (lilrb2) y usos para las mismas. |
| IL309345A (en) * | 2021-07-01 | 2024-02-01 | Albert Einstein College Medicine | Compositions and methods for inhibiting the expression of tmigd2 |
| EP4499683A1 (en) * | 2022-03-29 | 2025-02-05 | NGM Biopharmaceuticals, Inc. | Ilt3 and cd3 binding agents and methods of use thereof |
| WO2023235703A1 (en) * | 2022-05-31 | 2023-12-07 | Ngm Biopharmaceuticals, Inc. | Therapeutic methods using ilt-binding agents |
| CN114805580B (zh) * | 2022-06-28 | 2022-09-06 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| CN115975029B (zh) * | 2022-06-28 | 2026-05-29 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
| TW202409088A (zh) * | 2022-07-08 | 2024-03-01 | 中國商科望（蘇州）生物醫藥科技有限公司 | 抗lilrb2抗體及其用途 |
| WO2024022462A1 (zh) * | 2022-07-29 | 2024-02-01 | 盛禾(中国)生物制药有限公司 | 一种抗ilt4的单域抗体及其应用 |
| AU2023328075A1 (en) * | 2022-08-22 | 2025-04-03 | Antengene Biologics Limited | Novel anti-lilrb2 antibodies and uses thereof |
| AU2023337290A1 (en) * | 2022-09-08 | 2025-03-13 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anti-ilt4 antibody and pharmaceutical use thereof |
| WO2024073522A2 (en) * | 2022-09-28 | 2024-04-04 | Sparx Bioscience Limited | Antibodies binding to leukocyte immunoglobulin-like receptor subfamily b member 2 (lilrb2) and uses thereof |
| EP4637924A2 (en) * | 2022-12-23 | 2025-10-29 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| EP4491230A1 (en) * | 2023-07-14 | 2025-01-15 | iOmx Therapeutics AG | Cross-specific antigen binding proteins (abp) targeting leukocyte immunoglobulin-like receptor subfamily b1 (lilrb1) and lilrb2, combinations and uses thereof |
| JP2026504928A (ja) * | 2023-01-20 | 2026-02-10 | ワシントン・ユニバーシティ | Ｌｉｌｒｂ４／ｉｌｔ３アンタゴニスト組成物およびその使用方法 |
| CN116789826A (zh) * | 2023-05-12 | 2023-09-22 | 南京师范大学 | 抗人lilrb2全人源单域抗体及其应用 |
| CN119176874A (zh) * | 2023-06-21 | 2024-12-24 | 康源博创生物科技(北京)有限公司 | 一种能够结合lilrb2的抗体或其抗原结合片段 |
| WO2025128822A1 (en) * | 2023-12-12 | 2025-06-19 | The Methodist Hospital | Lilrb3 modulators and methods of use thereof |
| GB202319149D0 (en) * | 2023-12-14 | 2024-01-31 | Kbio Holdings Ltd | Antibody |
| CN121299117B (zh) * | 2025-12-05 | 2026-03-27 | 中国农业科学院都市农业研究所 | 检测猪轮状病毒的试剂和纳米酶免疫层析试纸条及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9688757B2 (en) | 2012-10-26 | 2017-06-27 | Deutsches Rheuma-Forschungszentrum Berlin | Bi-specific affinity reagents for cell-lineage-specific TNF-alpha neutralization |
| EP3339327A3 (en) * | 2013-02-28 | 2018-09-19 | National Cancer Center | Antibody against insoluble fibrin |
| EP2970373A1 (en) * | 2013-03-12 | 2016-01-20 | The Board of Trustees of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
| WO2015179633A1 (en) * | 2014-05-22 | 2015-11-26 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
| US20160200815A1 (en) * | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
| CA3218106A1 (en) * | 2015-03-06 | 2016-09-15 | The Board Of Regents Of The University Of Texas System | Anti-lilrb antibodies and their use in detecting and treating cancer |
| TWI780083B (zh) | 2016-11-18 | 2022-10-11 | 丹麥商賽門弗鎮公司 | 抗pd-1抗體及組成物 |
| TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗－ilt4抗體及抗原結合片段 |
-
2019
- 2019-09-17 JP JP2021539483A patent/JP2022501428A/ja active Pending
- 2019-09-17 AU AU2019343131A patent/AU2019343131A1/en not_active Abandoned
- 2019-09-17 CN CN201980075255.5A patent/CN113543804A/zh active Pending
- 2019-09-17 CA CA3111862A patent/CA3111862A1/en active Pending
- 2019-09-17 WO PCT/US2019/051529 patent/WO2020061059A1/en not_active Ceased
- 2019-09-17 KR KR1020217011459A patent/KR20210108940A/ko not_active Withdrawn
- 2019-09-17 EP EP19863793.6A patent/EP3852805A4/en not_active Withdrawn
- 2019-09-17 US US17/276,324 patent/US12157768B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12215163B2 (en) | CD25 antibodies | |
| US20240002515A1 (en) | Methods and antibodies for modulation of immunoresponse | |
| JP6839761B2 (ja) | 抗ＰＤ−Ｌ１抗体との組み合わせのための抗Ｔｉｍ−３抗体 | |
| EP3907240A1 (en) | Anti-tnfr2 antibody and use thereof | |
| KR102041832B1 (ko) | 췌장암의 치료 및/또는 예방용 의약 조성물 | |
| KR102052400B1 (ko) | 담낭암의 치료 및/또는 예방용 의약 조성물 | |
| CN109651507B (zh) | 一种激动型4-1bb单克隆抗体 | |
| US20170327580A1 (en) | Bispecific antibodies against cd3 epsilon and bcma for use in treatment of diseases | |
| KR20190028716A (ko) | Pd-l1-특이적 항체 및 이를 사용하는 방법 | |
| CN114555637A (zh) | 针对ilt2的抗体及其用途 | |
| KR20230058074A (ko) | Ilt2에 대한 항체 및 이의 용도 | |
| CA3253669A1 (en) | Anti-CD39 antibodies and their use | |
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| SG11202111192TA (en) | Dosing regimens of bispecific cd123 x cds diabodies in the treatment of hematologic malignancies | |
| EP3583127B1 (en) | Anti-programmed death-ligand 1 (pd-l1) antibodies and therapeutic uses thereof | |
| JP7681879B2 (ja) | Ｃｄ４３の固有のシアログリコシル化がん関連エピトープを標的化するモノクローナル抗体 | |
| TWI790193B (zh) | 調控免疫反應之方法及抗體 | |
| JP6881658B2 (ja) | Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療 | |
| EP4103611B1 (en) | Bispecific antibodies binding hvem and cd9 | |
| RU2793165C1 (ru) | Антитело против tnfr2 и его применение | |
| HK40117648A (en) | Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancer | |
| HK1244491A1 (en) | Bispecific antibodies against cd3epsilon and bcma for use in treatment of diseases |